These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1941 related articles for article (PubMed ID: 19765187)
1. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. Shin JY; Park HJ; Ahn YH; Lee PH J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187 [TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Liu LX; Chen WF; Xie JX; Wong MS Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104 [TBL] [Abstract][Full Text] [Related]
3. Neuroprotection in Parkinson models varies with toxin administration protocol. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378 [TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model. Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369 [TBL] [Abstract][Full Text] [Related]
5. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. Saporito MS; Brown EM; Miller MS; Carswell S J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541 [TBL] [Abstract][Full Text] [Related]
6. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922 [TBL] [Abstract][Full Text] [Related]
7. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364 [TBL] [Abstract][Full Text] [Related]
8. Toki-to protects dopaminergic neurons in the substantia nigra from neurotoxicity of MPTP in mice. Sakai R; Irie Y; Murata T; Ishige A; Anjiki N; Watanabe K Phytother Res; 2007 Sep; 21(9):868-73. PubMed ID: 17486689 [TBL] [Abstract][Full Text] [Related]
10. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease. Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. Schmidt N; Ferger B Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776 [TBL] [Abstract][Full Text] [Related]
13. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
14. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503 [TBL] [Abstract][Full Text] [Related]
15. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Pavón N; Martín AB; Mendialdua A; Moratalla R Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809 [TBL] [Abstract][Full Text] [Related]
16. Amiloride is neuroprotective in an MPTP model of Parkinson's disease. Arias RL; Sung ML; Vasylyev D; Zhang MY; Albinson K; Kubek K; Kagan N; Beyer C; Lin Q; Dwyer JM; Zaleska MM; Bowlby MR; Dunlop J; Monaghan M Neurobiol Dis; 2008 Sep; 31(3):334-41. PubMed ID: 18606547 [TBL] [Abstract][Full Text] [Related]
17. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732 [TBL] [Abstract][Full Text] [Related]
18. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Jourdain S; Morissette M; Morin N; Di Paolo T J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487 [TBL] [Abstract][Full Text] [Related]
19. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease. Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351 [TBL] [Abstract][Full Text] [Related]
20. Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. Jiang H; Li LJ; Wang J; Xie JX Exp Neurol; 2008 Aug; 212(2):532-7. PubMed ID: 18577498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]